Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta Altieri has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    No Detectable Hippocampal Subfield Volume Differences in Medication-Free Episodic Cluster Headache During Active Bouts: A 3 T MRI Cross-Sectional Study

    by Davide Chiffi, Antonio Di Renzo, Gianfranco De Stefano, Daniel Litewczuk, Cherubino Di Lorenzo, Alessandro De Maio, Alessio Colangelo, Daniele Carpentieri, Marco Fiorelli, Marta Altieri, et al.

    Background: Cluster headache is a severe primary headache disorder in which neuroimaging studies have suggested involvement of hypothalamic, limbic, and pain-related networks. Although hippocampal abnormalities have been reported in some studies, volumetric findings remain inconsistent and may depend on disease state, treatment exposure, chronicity, and imaging methodology. We explored whole hippocampus and hippocampal subfield volumes in medication-free patients with episodic cluster headache scanned interictally during an active bout. Methods: In this cross-sectional case–control study, 26 patients with episodic cluster headache (eCH) and 20 age- and sex-matched healthy controls underwent 3 T brain MRI. Patients were scanned during an active bout but outside acute headache attacks and had not received preventive treatment for at least three months before MRI acquisition. Automated hippocampus segmentation and subfield volumetry were performed using FreeSurfer 7.4.1, followed by visual quality control by two neuroradiologists. Group comparisons were adjusted for age, sex, and total intracranial volume. Multiple comparisons were addressed using Bonferroni correction for whole hippocampal volumes and false discovery rate (FDR) correction for subfield and clinical analyses. Results: No significant differences were detected between eCH patients and healthy controls in whole hippocampus or hippocampal subfield volumes after correction for multiple comparisons. Descriptive analyses showed numerically higher volumes in patients across several regions, but these effects were small to moderate and did not reach statistical significance. Exploratory analyses showed a nominal association between right fimbria volume and pain intensity; however, this association did not survive FDR correction. Conclusions: This study found no evidence of detectable hippocampal macrostructural differences in medication-free eCH patients scanned interictally during active bouts using 3 T MRI-based subfield volumetry. These null findings should not be interpreted as proof of preserved hippocampal structure, but rather as absence of measurable volumetric alterations within the limits of the present sample size, acquisition protocol, and analytical framework. Longitudinal and multimodal studies, including in-bout and out-of-bout assessments, higher-resolution imaging, and neuropsychological covariates, are needed to clarify whether hippocampal involvement in eCH is structural, microstructural, functional, or state-dependent.

  • SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia

    by Giada Giuliani, Chiara Zilli, Francesca Caramia, Vittorio Di Piero, Marta Altieri

    Background: Facial pain in multiple sclerosis is often due to trigeminal neuralgia but atypical pictures can be observed. Case presentation: A man with primary progressive multiple sclerosis developed severe unilateral facial pain in the right orbital region. Spontaneous and triggered attacks were associated with ipsilateral conjunctival injection and lacrimation. A diagnosis of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing was made, and symptoms significantly improved with lamotrigine. Conclusion: Pain is poorly investigated in multiple sclerosis, with a dramatic impact on patients’ life quality. In this light, standardized evaluation of pain is needed to improve patient management.


  • Open Access

    Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?

    by Arianna Di Stadio, Evanthia Bernitsas, Ignazio La Mantia, Michael J. Brenner, Massimo Ralli, Luigi Angelo Vaira, Andrea Colizza, Carlo Cavaliere, Matteo Laudani, Teresa C. Frohman, et al.

    Chronic olfactory dysfunction after SARS-CoV-2 infection occurs in approximately 10% of patients with COVID-19-induced anosmia, and it is a growing public health concern. A regimen of olfactory training and anti-neuroinflammatory therapy with co-ultramicronized palmitoylethanolamide with luteolin (um-PEA-LUT) has shown promising results in clinical trials; however, approximately 15% of treated patients do not achieve full recovery of a normal olfactory threshold, and almost 5% have no recovery. Disease-modifying therapies (DMTs), which are used to treat autoimmune neuroinflammation in multiple sclerosis (MS), have not been studied for treating persistent inflammation in refractory post-COVID-19 smell disorder. This study evaluated COVID-19-related smell loss and MS-related smell loss, comparing the responses to different therapies. Forty patients with MS and 45 reporting post-COVID-19 olfactory disorders were included in the study. All patients underwent nasal endoscopy and were evaluated by using validated Sniffin’ Sticks testing. The patients with long COVID were treated for three months with um-PEA-LUT plus olfactory training. The patients with MS were treated with DMTs. Olfactory functions before and after treatment were analyzed in both groups. At the experimental endpoint, 13 patients in the COVID-19 group treated with um-PEA-LUT had residual olfactory impairment versus 10 patients in the MS group treated with DMTs. The severity of the persistent olfactory loss was lower in the MS group, and the patients with MS treated with IFN-beta and glatiramer acetate had the preservation of olfactory function. These data provide a rationale for considering prospective trials investigating the efficacy of DMTs for post-COVID-19 olfactory disorders that are refractory to um-PEA-LUT with olfactory training. This study is the first to consider the role of DMT in treating refractory post-viral olfactory loss in patients with long COVID.


  • Open Access

    Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment

    by Carla Prezioso, Marco Ciotti, Gabriele Brazzini, Francesca Piacentini, Sara Passerini, Alfonso Grimaldi, Doriana Landi, Carolina Gabri Nicoletti, Maria Antonella Zingaropoli, Marco Iannetta, et al.

    Markers of JC polyomavirus (JCPyV) activity can be used to evaluate the risk of progressive multifocal leukoencephalopathy (PML) in treated multiple sclerosis (MS) patients. The presence of JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding control region (NCCR) in urine and plasma were determined in 42 MS subjects before treatment (T0), 6 months (T6) and 12 months (T12) after natalizumab, ocrelizumab, fingolimod or dimethyl-fumarate administration and in 25 healthy controls (HC). The number of MS patients with viruria increased from 43% at T0 to 100% at T12, whereas it remained similar for the HC group (35–40%). Viremia first occurred 6 months after treatment in MS patients and increased after 12 months, whereas it was absent in HC. The viral load in urine and plasma from the MS cohort increased over time, mostly pronounced in natalizumab-treated patients, whereas it persisted in HC. The archetypal NCCR was detected in all positive urine, whereas mutations were observed in plasma-derived NCCRs resulting in a more neurotropic variant. The prevalence and miR-J1-5p copy number in MS urine and plasma dropped after treatment, whereas they remained similar in HC specimens. Viruria and miR-J1-5p expression did not correlate with anti-JCV index. In conclusion, analyzing JCPyV DNA and miR-J1-5p levels may allow monitoring JCPyV activity and predicting MS patients at risk of developing PML.


  • Open Access

    Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology

    by Alessandro Viganò, Maria Claudia Torrieri, Massimiliano Toscano, Francesca Puledda, Barbara Petolicchio, Tullia Sasso D’eLia, Angela Verzina, Sonia Ruggiero, Marta Altieri, Edoardo Vicenzini, et al.

    Therapeutic management of Chronic Migraine (CM), often associated with Medication Overuse Headache (MOH), is chiefly empirical, as no biomarker predicting or correlating with clinical efficacy is available to address therapeutic choices. The present study searched for neurophysiological correlates of Greater Occipital Nerve Block (GON-B) effects in CM. We recruited 17 CM women, of whom 12 with MOH, and 19 healthy volunteers (HV). Patients had no preventive treatment since at least 3 months. After a 30-day baseline, they received a bilateral betamethasone-lidocaine GON-B of which the therapeutic effect was assessed 1 month later. Habituation of visual evoked potentials (VEP) and intensity dependence of auditory evoked potentials (IDAP) were recorded before and 1 week after the GON-B. At baseline, CM patients had a VEP habituation not different from HV, but a steeper IDAP value than HV (p = 0.01), suggestive of a lower serotonergic tone. GON-B significantly reduced the number of total headache days per month (− 34.9%; p = 0.003). Eight out 17CM patients reversed to episodic migraine and medication overuse resolved in 11 out of 12 patients. One week after the GON-B VEP habituation became lacking respect to baseline (p = 0.01) and to that of HV (p = 0.02) like in episodic migraine, while the IDAP slope significantly flattened (p < 0.0001). GON-B-induced reduction in headache days positively correlated with IDAP slope decrease (rho = 0.51, p = 0.03). GON-B may be effective in the treatment of CM, with or without MOH. The pre-treatment IDAP increase is compatible with a weak central serotonergic tone, which is strengthened after GON-B, suggesting that serotonergic mechanisms may play a role in CM and its reversion to episodic migraine. Since the degree of post-treatment IDAP decrease is correlated with clinical improvement, IDAP might be potentially useful as an early predictor of GON-B efficacy.


  • Depression after minor stroke: prevalence and predictors

    by M. Altieri, I. Maestrini, A. Mercurio, P. Troisi, E. Sgarlata, V. Rea, V. Di Piero, G. L. Lenzi

    Background and purpose:  Post‐stroke depression (PSD) is one of the most frequent complications of stroke, with a prevalence ranging 20–60%. As PSD seems to be related to stroke severity, we hypothesized that the prevalence of PSD would be lower in patients with minor stroke.Methods:  We investigated the prevalence and predictors of PSD over a 30‐month follow‐up period in a cohort of patients with minor ischaemic stroke (NIHSS ≤ 5).Results:  We enrolled 105 patients (mean age 64.38 ± 11.2 years, M/F 69/36). PSD was diagnosed in 43 (41%) patients, 40 (93%) of whom had dysthymia; 22% of patients were already depressed at 1 month. The most frequent depressive symptoms (DSs) were working inhibition, indecisiveness, and fatigability. Patients who developed PSD were less educated (P = 0.044) and diabetic (P = 0.006). After excluding patients that were already depressed at 1 month, we performed a logistic regression model to detect predictors of PSD. Crying (P = 0.012, OR 1.067, CI 0.269–4.553) and guilt (P = 0.007, OR 0.037, CI 0.02ì03–0.401) at baseline were two DSs found to be significantly correlated with PSD. Higher educational level (P = 0.022, OR 0.084, CI 0.010–0.698) and diabetes (P = 0.007, OR 14.361, CI 2.040–101.108) were the risk factors significantly correlated with PSD.Conclusion:  Post‐stroke depression is frequent even in patients with minor stroke. Early detection of DSs might help to predict long‐term development of PSD. No correlation was observed between lesion site or side and the development of PSD.


  • Open Access

    Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study

    by Stefano Bastianello, Alfredo Romani, Gisela Viselner, Enrico Colli Tibaldi, Elisabetta Giugni, Marta Altieri, Pietro Cecconi, Laura Mendozzi, Massimiliano Farina, Donatella Mariani, et al.

    Chronic cerebrospinal venous insufficiency (CCSVI) has recently been reported to be associated with multiple sclerosis (MS). However, its actual prevalence, possible association with specific MS phenotypes, and potential pathophysiological role are debated.


  • Combined Pharmacological and Short-Term Psychodynamic Psychotherapy for Probable Medication Overuse Headache: A Pilot Study

    by M Altieri, R Di Giambattista, L Di Clemente, D Fagiolo, E Tarolla, A Mercurio, E Vicenzini, L Tarsitani, Gl Lenzi, M Biondi, et al.

    We studied the effects of short-term psychodynamic psychotherapy (STPP) and pharmacological therapy in 26 consecutive patients with probable medication overuse headache (pMOH). Patients underwent a standard in-patient detoxification protocol, lasting a mean of 7 days. Eleven patients overused non-steroidal anti-inflammatory drugs (NSAIDs), five a combination of NSAIDs and triptans, four triptans, four a combination of NSAIDs, and three triptans and ergot derivates. Preventive therapy was initiated during detoxification. The STPP protocol comprised the Brief Psychodynamic Investigation (BPI) and psychoanalysis-inspired psychotherapy. All patients (groups A and B) underwent the BPI and pharmacological therapy. Half of the patients (group B) also not randomly underwent psychoanalysis-inspired psychotherapy. We found a significant interaction between time and group for headache frequency and medication intake. At 12-month follow-up, a statistically greater decrease in headache frequency and medication intake was observed in group B than in group A (P = 0.0108 and P = 0.0097, respectively). The relapse rate was much lower in group B patients at both 6 and 12 months [15.3%, odds ratio (OR) 0.11, P = 0.016, and 23%, OR 0.18, P = 0.047, respectively] than in group A. The risk of developing chronic migraine (CM) during follow-up was higher in group A than in group B at 6 (OR 2.0, P = 0.047) and 12 months (OR 2.75, P = 0.005). Our study suggests that STPP in conjunction with drug withdrawal and prophylactic pharmacotherapy relieves headache symptoms in pMOH, reducing both long-term relapses and the burden of CM.


  • Combined Transcranial Doppler and EEG Recording in Vasovagal Syncope

    by E. Vicenzini, S. Pro, S. Strano, P. Pulitano, M. Altieri, V. Di Piero, G.L. Lenzi, N. Accornero, O. Mecarelli

    Background: In neurally mediated syncope a ‘typical’ EEG pattern during hyperventilation (HV) may be observed. This study aimed to investigate transcranial Doppler (TCD) and EEG variations in response to hyper- and hypocapnia using simultaneous recording. Methods: Syncope patients with a typical EEG pattern during HV (SEEG+, n = 15) and those without abnormalities (SEEG–, n = 16) were compared with healthy controls (n = 20). Simultaneous TCD and EEG recordings were performed at rest (baseline), during 2 apnea tests and during HV. Cerebrovascular vasoreactivity, index for hypocapnia, total vasomotor reserve and time to flow velocity normalization after HV (t-norm) were recorded. Results: With TCD, a reduction in Vasomotor reserve was observed in SEEG+ compared with the other 2 groups (control: 67 ± 8%; SEEG–: 67 ± 10%; SEEG+: 57 ± 8%; p < 0.0001). t-norm was longer in all syncopal patients and in particular in SEEG+ (control: 20.2 ± 3 s; SEEG–: 40 ± 7 s; SEEG+: 123 ± 45s; p < 0.0001). Quantitative EEG showed an increase in slow bands in all subjects during HV, small and nonsignificant in controls and SEEG–, higher and significant in SEEG+, related with flow reduction. Conclusions: Changes in the sympathetic modulation of cerebral vasoconstriction may explain both the pathophysiology of vasovagal syncope and the typical paroxysmal EEG findings.


  • Trigeminal Neuralgia as the Sole Manifestation of an Arnold‐Chiari Type I Malformation: Case Report

    by Giovanni Caranci, Alessio Mercurio, Marta Altieri, Vittorio Di Piero

    Arnold‐Chiari type I malformations usually manifest clinically with short‐lasting headaches typically involving the occipital‐nuchal region and precipitated by the Valsalva maneuver, coughing, sudden postural change, or physical exertion. We describe the case of an adult patient who presented with symptomatic trigeminal neuralgia caused by an Arnold‐Chiari type I malformation. Unlike previous cases, the malformation involved the trigeminal ophthalmic division alone.